Opendata, web and dolomites

SDS-OmiProbe SIGNED

Revolutionary opto-biological methodology for aggressive HER2 cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SDS-OmiProbe project word cloud

Explore the words cloud of the SDS-OmiProbe project. It provides you a very rough idea of what is the project "SDS-OmiProbe" about.

tools    followed    performed    carries    striking    independent    rapid    cancer    annually    drugs    extracting    approximately    million       cellular    die    samples    biopsy    mortality    opto    tests    soa    revolutionary    methodology    optimization    tissue    realize    world    trials    breast    levels    realization    accuracy    sds    marker    tumours    biopsies    500    diagnosis    diagnostic    tool    gap    organization    concentration    billion    probe    essence    markers    close    expensive    companion    report    market    diagnosed    cell    opportunity    cancers    discordance    invasive    omiprobe    business    morbidity    disease    optic    causes    quantitative    subject    efficacy    global    clinical    vivo    health    trend    therapy    resolution    volume    landscape    transparency    worldwide    women    detects    according    biomarker    single    breakthrough    worth    fail    projected    14    compelling    instant    device    cells    biological    her2    laboratory    tip   

Project "SDS-OmiProbe" data sheet

The following table provides information about the project.

Coordinator
SDS OPTIC SPOLKA AKCYJNA 

Organization address
address: KONSTANTYNOW 1F
city: LUBLIN
postcode: 20 708
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Poland [PL]
 Project website https://sdsoptic.pl/
 Total cost 3˙985˙000 €
 EC max contribution 3˙985˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SDS OPTIC SPOLKA AKCYJNA PL (LUBLIN) coordinator 3˙985˙000.00

Map

 Project objective

According to World Health Organization, cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases per year. Breast cancer is the most common cancer among women, and is considered the second most common cancer overall. Each year about 1.7 million new cases are diagnosed worldwide and over 500,000 women die from the disease.

Current diagnosis methods of cancers fail to deliver objective results. Diagnosis require extracting tissue samples via invasive and expensive biopsy, followed by laboratory analysis, which are subject to significant levels of discordance.

SDS Optic presents a revolutionary opto-biological methodology that allows for instant cellular processes studies including in-vivo cancer diagnosis with single-cell resolution. SDS-OmiProbe detects presence and measures concentration levels of the HER2 cancer cells in breast tumours. It is a breakthrough device that carries the potential to address the challenges of SoA cancer markers diagnosis and biopsies. In essence, it is a laboratory test at the tip of a probe, but with greater accuracy, efficacy and quantitative results. SDS-OmiProbe may also be used as a companion diagnostic tool for targeted therapy and targeted therapy drugs.

There is compelling evidence that our novel SDS-OmiProbe is addressing a rapid growth trend in a high volume market. Based on Transparency Market Research Report the OmiProbe target market of HER2- biomarker tests is projected to be worth $4.6 billion, with 7.5 million HER2 marker tests performed annually worldwide.

In order to close the striking gap in the landscape of currently available cancer diagnostic and targeted therapy tools, and to realize the significant global business opportunity the objective of this project is optimization of the SDS-OmiProbe device, followed by realization of independent clinical trials and dissemination of the results.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SDS-OMIPROBE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SDS-OMIPROBE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More